Chemoprevention of Oral Premalignant Lesions
Reduction in size and number of oral premalignant lesions
Precancerous Conditions
DRUG: Celecoxib
To evaluate the efficacy of celecoxib in subjects with Early or Advanced oral premalignant lesion (OPL)|by both clinical response (reduction in size of all lesions,|prevention of growth in the index lesion and of any new lesions)|and histological response (change in histological grade).|To evaluate the safety of chronic multiple dosing of celecoxib in this patient population.
To evaluate the treatment effects in modulating the expression of genomic and proliferative markers after 12 weeks of treatment with study drug, followed by 12 weeks off study drug.
Reduction in size and number of oral premalignant lesions